Karyopharm Therapeutics Inc. (NASDAQ: KPTI) announced that its Phase 3 SENTRY trial of selinexor combined with ruxolitinib in myelofibrosis patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE